Investigation of Tipifarnib in Treatment of Subjects With Peripheral T-Cell Lymphoma (PTCL) That Have Not Responded to Standard Therapy

NCT02464228 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

65

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed or Refractory Peripheral T-Cell Lymphoma

Interventions

DRUG: Tipifarnib

Sponsor

Kura Oncology, Inc.